PE20040990A1 - Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos - Google Patents

Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos

Info

Publication number
PE20040990A1
PE20040990A1 PE2003000768A PE2003000768A PE20040990A1 PE 20040990 A1 PE20040990 A1 PE 20040990A1 PE 2003000768 A PE2003000768 A PE 2003000768A PE 2003000768 A PE2003000768 A PE 2003000768A PE 20040990 A1 PE20040990 A1 PE 20040990A1
Authority
PE
Peru
Prior art keywords
erb
combinations
kinase inhibitors
antineoplastic drugs
refers
Prior art date
Application number
PE2003000768A
Other languages
English (en)
Spanish (es)
Inventor
David William Fry
William Leon Elliott
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20040990A1 publication Critical patent/PE20040990A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2003000768A 2002-08-07 2003-08-04 Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos PE20040990A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11

Publications (1)

Publication Number Publication Date
PE20040990A1 true PE20040990A1 (es) 2004-12-27

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000768A PE20040990A1 (es) 2002-08-07 2003-08-04 Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos

Country Status (17)

Country Link
US (2) US20040067942A1 (https=)
EP (1) EP1549320A1 (https=)
JP (1) JP2005538129A (https=)
CN (1) CN1674908A (https=)
AR (1) AR040792A1 (https=)
AU (1) AU2003249450A1 (https=)
BR (1) BR0313470A (https=)
CA (1) CA2494270A1 (https=)
IL (1) IL166423A0 (https=)
MX (1) MXPA05001430A (https=)
NO (1) NO20051170L (https=)
PA (1) PA8578001A1 (https=)
PE (1) PE20040990A1 (https=)
PL (1) PL375414A1 (https=)
RU (1) RU2005102836A (https=)
TW (1) TW200404532A (https=)
WO (1) WO2004014386A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) * 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
RU2413731C2 (ru) 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
CN1972688B (zh) 2004-05-06 2012-06-27 沃尼尔·朗伯有限责任公司 4-苯胺基-喹唑啉-6-基-酰胺类化合物
BRPI0510657A (pt) 2004-06-03 2007-12-04 Hoffmann La Roche tratamento com cisplatina e com um inibidor de egfr
EP1755608A1 (en) * 2004-06-03 2007-02-28 F.Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
WO2005117877A1 (en) * 2004-06-03 2005-12-15 F.Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
RU2325199C2 (ru) * 2006-06-20 2008-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ комбинированного лечения местно-распространенных форм рака шейки матки
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CN103596592A (zh) * 2011-05-06 2014-02-19 梅里麦克制药股份有限公司 用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
WO2021178789A1 (en) * 2020-03-06 2021-09-10 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of different cancerous disorders
CN118576599A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors

Also Published As

Publication number Publication date
BR0313470A (pt) 2005-06-21
EP1549320A1 (en) 2005-07-06
CN1674908A (zh) 2005-09-28
PA8578001A1 (es) 2004-05-07
WO2004014386A1 (en) 2004-02-19
TW200404532A (en) 2004-04-01
JP2005538129A (ja) 2005-12-15
MXPA05001430A (es) 2005-06-06
AR040792A1 (es) 2005-04-20
US20040067942A1 (en) 2004-04-08
US20060293323A1 (en) 2006-12-28
IL166423A0 (en) 2006-01-15
NO20051170L (no) 2005-05-06
RU2005102836A (ru) 2005-08-10
PL375414A1 (en) 2005-11-28
CA2494270A1 (en) 2004-02-19
AU2003249450A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
PE20040990A1 (es) Combinaciones de inhibidores de quinasa de erb b y farmacos antineoplasicos
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
MX2024010045A (es) Compuestos de quinazolina y uso de los mismos como inhibidores de proteinas mutantes kras.
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
AR059203A1 (es) Composiciones para uso vaginal
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
NO20082292L (no) Antiproliferativ kombinasjonsterapi ved anvendelse av visse platinumbaserte kjemoterapeutiske virekemiddel og EGFR inhibitorer eller pyrimidine analoger
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
UY28441A1 (es) Derivados de quinazolina
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
ECSP088598A (es) Derivados de piridazinona
GT200100037A (es) Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina y que depende de la ciclina.
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
TW201613644A (en) Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
ATE456370T1 (de) Kombinationsprodukt bestehend aus einem inhibitor der src familie der nicht-rezeptor tyrosinkinasen und gemcitabin zur behandlung oder prophylaxe von pankreaskrebs
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
ATE365163T1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal